Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

28.09 -0.05 (-0.18%)
Official Closing Price Updated: 7:00 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Breaking Down Hims & Hers Health: 13 Analysts Share Their Views
Via Benzinga
2 Reasons to Like HIMS and 1 to Stay Skeptical
Since April 2020, the S&P 500 has delivered a total return of 92.9%. But one standout stock has nearly doubled the market - over the past five years, Hims & Hers Health has surged 172% to $26.89 per... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Is the Market Bullish or Bearish on Hims & Hers Health?
Via Benzinga
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide
Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding. 
Via The Motley Fool
Healthcare Technology Stocks Q4 In Review: Hims & Hers Health (NYSE:HIMS) Vs Peers
Let’s dig into the relative performance of Hims & Hers Health (NYSE:HIMS) and its peers as we unravel the now-completed Q4 healthcare technology earnings season. 
Via StockStory
Robinhood, AppLovin, Hims & Hers Health, Sleep Number, and Covenant Logistics Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after Federal Reserve Chair Jerome Powell signaled a cautious stance on future monetary policy decisions during a speech in Chicago, emphasizing that... 
Via StockStory
Topics Economy Government World Trade
Exposures Economy Interest Rates Political
Hims’ Weight Loss Expansion: Real Growth or Just Hype?
Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite? 
Via MarketBeat
Exposures Product Safety
Exploring the Growth Potential of HIMS & HERS HEALTH INC (NYSE:HIMS) as It Nears a Breakout.
Based on technical and fundamental analysis of NYSE:HIMS we find: HIMS & HERS HEALTH INC (NYSE:HIMS) qualifies as a high growth stock and is consolidating. 
Via Chartmill
PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump announced a 90-day tariff pause. Reciprocal tariffs were also dropped to 10% for most... 
Via StockStory
Topics Artificial Intelligence Government World Trade
Exposures Artificial Intelligence Political Tariff
Why Hims & Hers Health Stock Couldn't Beat the Market Today
Via The Motley Fool
What's Driving the Market Sentiment Around Hims & Hers Health?
Via Benzinga
Hims Dives After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch
It's true, the company can sell Lilly's tirzepatide. But that doesn't mean patients will buy it. 
Via Investor's Business Daily
nCino Posts Weak Earnings, Joins Tesla And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Newsmax, Waton Financial, Johnson & Johnson, Hims & Hers Health, Tesla: Why These 5 Stocks Are On Investors' Radars Today
U.S. stocks closed higher on Tuesday, with the Nasdaq Composite climbing 0.9% to 17,449.89. The S&P 500 added nearly 0.4%, finishing at 5,633.07. 
Via Benzinga
Topics Stocks
Exposures US Equities
Hims & Hers Adds Eli Lilly's Zepbound To Weight-Loss Offerings: Retail Excited Despite BofA Seeing 'Immaterial' Sales Impact
According to Bloomberg, a monthly prescription of Zepbound via Hims' platform would cost $1,899 — $800 more than Lilly's list price for the drug. 
Via Stocktwits
Why Hims & Hers Health Stock Soared Tuesday
Via The Motley Fool
Topics Stocks
Exposures US Equities
Hims & Hers Health Stock Jumped Tuesday Afternoon: What Happened?
Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer Eli Lilly And Co's (NYSE:LLY) Zepbound through its Telehealth platform. 
Via Benzinga
Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.5% in the afternoon session after the company revealed it will offer Eli Lilly's weight-loss medications (Zepbound) on its... 
Via StockStory
Topics Artificial Intelligence Supply Chain
Exposures Artificial Intelligence Product Safety Supply Chain
Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound
The deal allows Hims & Hers to sell Eli Lilly's Zepbound on its telehealth platform. 
Via Investor's Business Daily
Exposures Product Safety
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating
JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities. 
Via MarketBeat
1 Stock Under $50 on Our Watchlist and 2 to Turn Down
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
Is Hims & Hers Stock Too Cheap to Pass Up?
This high-growth stock may be cheaper than you think. 
Via The Motley Fool
Smart Money Is Betting Big In HIMS Options
Via Benzinga
Is Hims & Hers Health Stock a Smart Buy After Plunging More Than 50%?
Via The Motley Fool
Topics Earnings
Exposures Financial Product Safety
Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped
There's a price war brewing in GLP-1 weight loss drugs, and now it's going global. 
Via The Motley Fool
Hims & Hers Health's Options Frenzy: What You Need to Know
Via Benzinga
Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 8% in the afternoon session after the U.S. Food and Drug Administration raised concerns about unapproved GLP-1 drugs used for weight... 
Via StockStory
Topics Supply Chain
Exposures Product Safety Supply Chain
Why Hims & Hers Stock Tumbled on Tuesday
Bank of America just delivered an incredibly back-handed compliment to Hims & Hers stock. 
Via The Motley Fool
2 Healthcare Stocks with Solid Fundamentals and 1 to Brush Off
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.